GLPBio

Fadrozole

Catalog No.: GC19151Purity:>99.50%
Fadrozol (freie Base CGS 16949A) ist ein potenter, selektiver und nichtsteroidaler Aromatasehemmer mit einem IC50 von 6,4 nM.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


Fadrozole
Cas No.: 102676-47-1
5mgIn Stock
$44.00
1
10mgIn Stock
$59.00
1
25mgIn Stock
$97.00
1
50mgIn Stock
$174.00
1
100mgIn Stock
$308.00
1

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

Fadrozole (CGS 16949A) is a selective, non-steroidal aromatase inhibitor with an IC50 value of 4.5μM[1]. Fadrozole has been investigated as a treatment of hormone-responsive breast cancer (estrogen sensitive)[1]. Aromatase is an enzyme that plays a vital role in converting androgens (like testosterone) into estrogens (like estradiol). Fadrozole can be used to block aromatase and reduces the level of estrogens[2].

In vitro, prolactin-positive cells were extracted from male Wistar rats. By treating prolactin-positive cells with 1μM Fadrozole alone for 1, 3, 6 or 12 hours respectively, no statistically significant variations in the cellular area and proliferation rates were observed due to absent testosterone and minimal synthesized estradiol[3]. When treating cells with 1μM Fadrozole and 1μM testosterone, significantly decreased of the size of prolactin-positive cells as well as reduced percentage of proliferation rates were obtained from 3 to 12 hours treatment[3].

In vivo, Fadrozole (300μg/day) was inplantated with mini-osmotic pumps on day 14 of pregnancy Sprague–Dawley rats to reduce the level of estradiol-17 (E2)[4]. Fadrozole (1200μg; 4 days) resulted in a significant reduced E2 concentration and high level of androstenedione and testosterone in pregnant rats[4]. Fadrozole (1800μg; 6 days) led to a fourfold increased intrauterine pressure with significant smaller uterine tissue framework in pregnant rats[2,4]. Fadrozole caused fetal abnormalities in pregnant rats, where 20% of fetuses had head injuries while their weight did not differ from normal fetuses[4].

References:
[1] Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. Journal of medicinal chemistry. 1991 Feb;34(2):725-36.
[2] Tiboni GM, Ponzano A. Fetal safety profile of aromatase inhibitors: Animal data. Reproductive Toxicology. 2016 Dec 1;66:84-92.
[3] Patil CN, Li W, Wang X. Local transformations of androgens into estradiol by aromatase P450 are involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells. J Endocrinol. 2014;222(2):201–12. doi:10.1530/JOE-13-0579.
[4] Tamada H, Shimizu Y, Inaba T, Kawate N, Sawada T. The effects of the aromatase inhibitor fadrozole hydrochloride on fetuses and uteri in late pregnant rats. Journal of endocrinology. 2004 Feb 1;180(2):337-46.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

Prolactin-positive cells

Preparation Method

Male Wistar rats (175–200g) were killed to extract prolactin-positive cells. Prolactin-positive cells were seeded on 60 culture chamber slides at a final concertation of 2.5×105/ml cells and incubated with Dulbecco’s modified Eagle’s medium (DMEM) for 7 days. On day 4, medium was changed by fresh DMEM. On day 7, cell cultures were treated with 1μM testosterone, 1μM Fadrozole and incubated for 1, 3, 6 or 12 hours (5 chambers per treatment). After treatment, the chambers were washed with Dubelcco’s sterile PBS, and cells were fixed in Somogy’s solution for 1 hour, followed by rinsing in PBS.

Reaction Conditions

1μM testosterone, 1μM Fadrozole; 1, 3, 6 or 12 hours

Applications

Fadrozole alone did not affect prolactin-positive cells. Combination of Fadrozole and testosterone significantly decreases prolactin-positive cells sizes and proliferation rates.

Animal experiment [2]:

Animal models

Sprague–Dawley female rats

Preparation Method

Female rats (180-300g) were mated when 60-120 days old. On day 14 of pregnancy rats were divided into three groups. Group 1 (Fad) rats were implanted s.c. with mini-osmotic pumps containing Fadrozole (300μg/day). Group 2 (control) rats were implanted s.c. with mini-osmotic pumps containing saline. Group 3 (Fad+E2) rats were implanted s.c. with mini-osmotic pumps containing Fadrozole (300μg/day) and estradiol-17 (E2) (0.2μg/day, E2 was dissolved in 0.2ml sesame oil). On day 17 of pregnancy, blood samples were collected from the abdominal aorta of rats in all 3 groups. On day 20 of pregnancy, all 3 groups rats underwent laparotomy under ether anesthesia.

Dosage form

Fadrozole: 300μg/day for 6 days; estradiol-17: 0.2μg/day for 6 days

Applications

Fadrozole treatment significantly reduced E2 concentration, and led to a fourfold increased intrauterine pressure with smaller uterine tissue framework in pregnant rats. Fadrozole caused fetal abnormalities in pregnant rats, but their weight did not differ from normal fetuses. The combination treatment of Fadrozole and E2 had similar effect as control groups, indicating that exogenously supplied E2 could compensate for the loss of endogenous E2.

References:
[1] Patil CN, Li W, Wang X. Local transformations of androgens into estradiol by aromatase P450 are involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells. J Endocrinol. 2014;222(2):201–12. doi:10.1530/JOE-13-0579.
[2] Tamada H, Shimizu Y, Inaba T, Kawate N, Sawada T. The effects of the aromatase inhibitor fadrozole hydrochloride on fetuses and uteri in late pregnant rats. Journal of endocrinology. 2004 Feb 1;180(2):337-46.

Produktdokumente (Product Documents)

Purity:>99.50%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
102676-47-1
SMILES
N#CC1=CC=C(C2CCCC3=CN=CN23)C=C1
Summenformel
C14H13N3
Molekulargewicht
223.27
Löslichkeit
DMSO : ≥ 100 mg/mL (447.89 mM)
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for Fadrozole

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%